The DC Federal District Court’s ruling to stop reforms to Medicare payment for drugs acquired under the 340B drug discount program is unfortunate because it undermines HHS efforts to cut drug costs and promote fairer […]
Read More… from FAH Leader Expresses Opposition to Ruling that Overturns 340B Medicare Regulation
This afternoon FAH President and CEO Chip Kahn and AHA President and CEO Rick Pollack sent a joint letter to leaders in Congress addressing the issue of surprise billing highlighting the need to find a […]
Read More… from FAH, AHA Send Joint Letter to Congress on Surprise Billing
Today, the FAH commented on the Administration’s proposal to expand the use of health reimbursement arrangements (HRAs). Under the proposal, employers would be allowed to reimburse their employees through the use of a HRA for […]
Read More… from FAH Comments on Proposed Rule Expanding Use of HRAs
Today, the FAH commented on the Administration’s action, replacing existing guidance for Section 1332 waivers that give states an opportunity to opt out of certain requirements set forth by the Affordable Care Act (ACA). The […]
